PYM Phytopharm

TIDMIXI

IXICO plc

18 July 2017

18 July 2017

IXICO plc

("IXICO" or the "Company")

IXICO hosts Alzheimer Expert Symposium

Accelerating the development of treatments for Alzheimer's disease

Coinciding with the Alzheimer's Association International Conference in London's Historic Tower Bridge

18 July 2017, IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, is today holding an Expert Symposium on the impact and future of imaging and digital biomarkers in Alzheimer's disease. The symposium is set to coincide with the Alzheimer's Association International Conference (AAIC) in London, UK.

Speakers include Frederik Barkhof, AMYPAD Project Coordinator and Professor of Neuroradiology at VUmc and UCL and Derek Hill, President of Regulatory Science and External Relations at IXICO.

A key highlight will be a discussion on the Amyloid Imaging to Prevent Alzheimer' Disease (AMYPAD) programme, which is a collaboration between leading academic, healthcare and pharmaceutical partners. AMYPAD's two key objectives are to advance the use of amyloid brain scans to improve the diagnosis of Alzheimer's disease and to better select the right patients, earlier in the disease course, for clinical trials targeting the prevention of Alzheimer's disease.

Derek Hill said: "AMYPAD is an important initiative focused on preventing Alzheimer's disease, which has a significant unmet medical need but due to the nature of the disease, is scientifically challenging. IXICO is proud to participate in this programme and to bring to bear our skills and expertise in neurology alongside our pharma and scientific partners. Frederik and I look forward to an engaging discussion in such an iconic venue, here in London."

IXICO's team will also present automated data analysis methods for enriching and phenotyping patients, the standardisation of quantitative amyloid imaging biomarkers together with the validation and regulatory path for biosensor based digital biomarkers and their application in Alzheimer's disease clinical trials.

The symposium takes place at Tower Bridge and recordings of the evening's speakers and discussion will be available as a webinar following the event.

For further information please contact:

 
 IXICO plc 
  Giulio Cerroni, Chief Executive     Tel: +44 20 3763 
  Officer                             7499 
  Susan Lowther, Chief Financial 
  Officer 
 
 FTI Consulting Limited (Investor   Tel: +44 20 3727 
  Relations)                         1000 
  Simon Conway / Mo Noonan 
 

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes. More information is available on www.IXICO.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADMGMNMNKGNZZ

(END) Dow Jones Newswires

July 18, 2017 02:01 ET (06:01 GMT)

Phytopharm (LSE:PYM)
Historical Stock Chart
From Apr 2024 to May 2024

Phytopharm (LSE:PYM)
Historical Stock Chart
From May 2023 to May 2024